SCHEMBL4728647

SCHEMBL4728647

CN(C)Cc1cc2ccccc2[nH]1

nearest known ligand 0.70

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.58
HRH4 Q9H3N8 1/20 0.49
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47
HRH3 Q9Y5N1 1/20 0.46
AHR P35869 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29750394 1.00 LOXL2 (0.58) LOXL2HRH4MTNR1AMTNR1BHRH3
SCHEMBL7067817 0.84 LOXL2 (0.50) LOXL2HRH4MTNR1AMTNR1BHRH3
SCHEMBL28545346 0.84 LOXL2 (0.62) LOXL2HRH4MTNR1AMTNR1BHRH3
SCHEMBL16771656 0.82 LOXL2 (0.51) LOXL2HRH4MTNR1AMTNR1BAHR
SCHEMBL30594269 0.82 LOXL2 (0.51) LOXL2HRH4MTNR1AMTNR1BAHR
SCHEMBL8570896 0.81 LOXL2 (0.55) LOXL2HRH4MTNR1AMTNR1BHRH3
SCHEMBL8574842 0.81 LOXL2 (0.55) LOXL2HRH4MTNR1AMTNR1BHRH3
SCHEMBL29368759 0.79 PYCR1 (0.54) LOXL2HRH4
SCHEMBL108061 0.78 LOXL2 (0.64) LOXL2HRH4MTNR1AMTNR1BHRH3
SCHEMBL29375490 0.78 LOXL2 (0.64) LOXL2HRH4MTNR1AMTNR1BHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0506532-A1 Indole derivatives, process for their preparation and medicaments containing them LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1992-09-30 EP claimed
US-12281099-B2 Isoindolinone substituted indoles and derivatives as RAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-04-22 US disclosed
EP-3931188-B1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-08-30 EP disclosed
EP-3931188-B1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-08-30 EP disclosed
US-20220144810-A1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-12 US disclosed
US-20220144810-A1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-12 US disclosed
CN-109422754-A Pyrazolo [3,4-d] pyrimidine -3- ketone derivatives, its pharmaceutical composition and application 上海迪诺医药科技有限公司 2019-03-05 CN disclosed
CN-109364004-A A kind of skin-care gel containing Maltsupex 拉芳家化股份有限公司 2019-02-22 CN disclosed
CN-106905300-B Giantreed alkali derivant and its pharmaceutical composition and its application in pharmacy 中国科学院昆明植物研究所 2019-01-22 CN disclosed
CN-107174586-A Using giantreed alkali derivant as the pharmaceutical composition of active component and its application 中国科学院昆明植物研究所 2017-09-19 CN disclosed
EP-0985674-A1 ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS MITSUBISHI CHEMICAL CORPORATION (JP) 2000-03-15 EP disclosed
EP-0695755-B1 Pyrrolocarbazole HOFFMANN LA ROCHE (CH) 1998-10-21 EP disclosed
US-5721267-A ANTICANCER AGENTS SYNTEX (U.S.A.) INC. (US) 1998-02-24 US disclosed
EP-0695755-A1 Pyrrolocarbazoles F. Hoffmann-La Roche AG (CH) 1996-02-07 EP disclosed
US-5219859-A Chloesterol acyltransferase inhibitors; antilipemic agents; antidiabetic agents; atherosclerosis LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1993-06-15 US disclosed
EP-0506532-A1 Indole derivatives, process for their preparation and medicaments containing them LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) 1992-09-30 EP disclosed
EP-0037271-B1 INDOLE DERIVATIVES AND PROCESS FOR PREPARING THE SAME TORAY INDUSTRIES, INC. (JP) 1984-01-18 EP disclosed
US-4399289-A STABLE TRYPTOPHANE INTERMEDIATES TORAY INDUSTRIES, INC. (JP) 1983-08-16 US disclosed
EP-0037271-A1 Indole derivatives and process for preparing the same TORAY INDUSTRIES, INC. (JP) 1981-10-07 EP disclosed
US-4154735-A FUNGICIDES, DEPRESSANTS WARNER-LAMBERT COMPANY (US) 1979-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281099-B2 Isoindolinone substituted indoles and derivatives as RAS inhibitors NRAS, KRAS, RASSF5 LOXL2 4662/4885HRH4 1330/4885MTNR1A 1048/4885
US-20220144810-A1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS NRAS, RASSF5, KRAS LOXL2 4649/4885HRH4 1268/4885MTNR1A 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.